Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Autor:	He J; Foundation Medicine, Cambridge, MA;, Abdel-Wahab O; Leukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program., Nahas MK; Foundation Medicine, Cambridge, MA;, Wang K; Foundation Medicine, Cambridge, MA;, Rampal RK; Leukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program., Intlekofer AM; Cancer Biology and Genetics Program, Lymphoma Service, Department of Medicine., Patel J; Human Oncology and Pathogenesis Program., Krivstov A; Cancer Biology and Genetics Program, Leukemia Center, Department of Pediatrics, and., Frampton GM; Foundation Medicine, Cambridge, MA;, Young LE; Foundation Medicine, Cambridge, MA;, Zhong S; Foundation Medicine, Cambridge, MA;, Bailey M; Foundation Medicine, Cambridge, MA;, White JR; Foundation Medicine, Cambridge, MA;, Roels S; Foundation Medicine, Cambridge, MA;, Deffenbaugh J; Foundation Medicine, Cambridge, MA;, Fichtenholtz A; Foundation Medicine, Cambridge, MA;, Brennan T; Foundation Medicine, Cambridge, MA;, Rosenzweig M; Foundation Medicine, Cambridge, MA;, Pelak K; Foundation Medicine, Cambridge, MA;, Knapp KM; Leukemia Center., Brennan KW; Foundation Medicine, Cambridge, MA;, Donahue AL; Foundation Medicine, Cambridge, MA;, Young G; Foundation Medicine, Cambridge, MA;, Garcia L; Foundation Medicine, Cambridge, MA;, Beckstrom ST; Foundation Medicine, Cambridge, MA;, Zhao M; Foundation Medicine, Cambridge, MA;, White E; Foundation Medicine, Cambridge, MA;, Banning V; Foundation Medicine, Cambridge, MA;, Buell J; Foundation Medicine, Cambridge, MA;, Iwanik K; Foundation Medicine, Cambridge, MA;, Ross JS; Foundation Medicine, Cambridge, MA;, Morosini D; Foundation Medicine, Cambridge, MA;, Younes A; Lymphoma Service, Department of Medicine., Hanash AM; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;, Paietta E; Department of Medicine (Oncology), Albert Einstein College of Medicine, Yeshiva University, New York, NY;, Roberts K; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN;, Mullighan C; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN;, Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY;, Armstrong SA; Cancer Biology and Genetics Program, Leukemia Center, Department of Pediatrics, and., Mughal T; Foundation Medicine, Cambridge, MA; Division of Hematology and Oncology, Tufts University Medical Center, Boston, MA; and., Vergilio JA; Foundation Medicine, Cambridge, MA;, Labrecque E; Foundation Medicine, Cambridge, MA;, Erlich R; Foundation Medicine, Cambridge, MA;, Vietz C; Foundation Medicine, Cambridge, MA;, Yelensky R; Foundation Medicine, Cambridge, MA;, Stephens PJ; Foundation Medicine, Cambridge, MA;, Miller VA; Foundation Medicine, Cambridge, MA;, van den Brink MR; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Otto GA; Foundation Medicine, Cambridge, MA;, Lipson D; Foundation Medicine, Cambridge, MA;, Levine RL; Leukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program, Leukemia Center.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2016 Jun 16; Vol. 127 (24), pp. 3004-14. Date of Electronic Publication: 2016 Mar 10.
DOI:	10.1182/blood-2015-08-664649
Abstrakt:	The spectrum of somatic alterations in hematologic malignancies includes substitutions, insertions/deletions (indels), copy number alterations (CNAs), and a wide range of gene fusions; no current clinically available single assay captures the different types of alterations. We developed a novel next-generation sequencing-based assay to identify all classes of genomic alterations using archived formalin-fixed paraffin-embedded blood and bone marrow samples with high accuracy in a clinically relevant time frame, which is performed in our Clinical Laboratory Improvement Amendments-certified College of American Pathologists-accredited laboratory. Targeted capture of DNA/RNA and next-generation sequencing reliably identifies substitutions, indels, CNAs, and gene fusions, with similar accuracy to lower-throughput assays that focus on specific genes and types of genomic alterations. Profiling of 3696 samples identified recurrent somatic alterations that impact diagnosis, prognosis, and therapy selection. This comprehensive genomic profiling approach has proved effective in detecting all types of genomic alterations, including fusion transcripts, which increases the ability to identify clinically relevant genomic alterations with therapeutic relevance. (© 2016 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu